Biodistribution and Cellular Internalization of Inactivated SARS-CoV-2 in Wild-Type Mice.
SARS-CoV-2
cellular uptake
heparan sulfate proteoglycans
mouse
syndecans
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Jul 2022
09 Jul 2022
Historique:
received:
01
06
2022
revised:
04
07
2022
accepted:
07
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Despite the growing list of identified SARS-CoV-2 receptors, the human angiotensin-converting enzyme 2 (ACE2) is still viewed as the main cell entry receptor mediating SARS-CoV-2 internalization. It has been reported that wild-type mice, like other rodent species of the Muridae family, cannot be infected with SARS-CoV-2 due to differences in their ACE2 receptors. On the other hand, the consensus heparin-binding motif of SARS-CoV-2's spike protein, PRRAR, enables the attachment to rodent heparan sulfate proteoglycans (HSPGs), including syndecans, a transmembrane HSPG family with a well-established role in clathrin- and caveolin-independent endocytosis. As mammalian syndecans possess a relatively conserved structure, we analyzed the cellular uptake of inactivated SARS-CoV-2 particles in in vitro and in vivo mice models. Cellular studies revealed efficient uptake into murine cell lines with established syndecan-4 expression. After intravenous administration, inactivated SARS-CoV-2 was taken up by several organs in vivo and could also be detected in the brain. Internalized by various tissues, inactivated SARS-CoV-2 raised tissue TNF-α levels, especially in the heart, reflecting the onset of inflammation. Our studies on in vitro and in vivo mice models thus shed light on unknown details of SARS-CoV-2 internalization and help broaden the understanding of the molecular interactions of SARS-CoV-2.
Identifiants
pubmed: 35886958
pii: ijms23147609
doi: 10.3390/ijms23147609
pmc: PMC9316427
pii:
doi:
Substances chimiques
Heparan Sulfate Proteoglycans
0
Syndecans
0
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Innovative Medicines Initiative
ID : 807015
Organisme : European Union
ID : 863214
Organisme : National Research, Development and Innovation Office
ID : 2017-2.3.6-TÉT-CN-2018-00023
Organisme : National Research, Development and Innovation Office
ID : 2020-1.1.6-JÖVŐ-2021-00012
Références
Cell. 2020 Dec 10;183(6):1520-1535.e14
pubmed: 33157038
J Biol Chem. 1990 Apr 25;265(12):6884-9
pubmed: 2324102
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
Mol Microbiol. 2022 Jun;117(6):1308-1316
pubmed: 35434857
Sci Rep. 2019 Feb 4;9(1):1393
pubmed: 30718543
J Virol. 2004 Jun;78(12):6567-84
pubmed: 15163749
Bioessays. 1998 Feb;20(2):156-67
pubmed: 9631661
Int J Mol Sci. 2022 Apr 20;23(9):
pubmed: 35562967
J Cell Biol. 1996 Apr;133(2):405-16
pubmed: 8609172
Lung. 2020 Dec;198(6):867-877
pubmed: 33170317
Mol Biol Cell. 2001 Feb;12(2):339-50
pubmed: 11179419
Signal Transduct Target Ther. 2022 Mar 11;7(1):83
pubmed: 35277473
Int J Mol Sci. 2021 May 19;22(10):
pubmed: 34069441
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Biol Chem. 2000 Mar 31;275(13):9410-7
pubmed: 10734086
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054983
Sci Rep. 2019 Nov 12;9(1):16543
pubmed: 31719623
J Biol Chem. 2022 Mar;298(3):101710
pubmed: 35150743
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
Biochim Biophys Acta. 2010 Dec;1798(12):2258-65
pubmed: 20138023
Arteriosclerosis. 1989 Jan-Feb;9(1):21-32
pubmed: 2463827
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
Transbound Emerg Dis. 2021 Jul 5;:
pubmed: 34224205
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Connect Tissue Res. 2015;56(4):272-80
pubmed: 26076122
J Biophys Biochem Cytol. 1961 Dec;11:736-9
pubmed: 14474176
J Biol Chem. 2013 May 17;288(20):13988-13999
pubmed: 23525115
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207476
J Biol Chem. 2022 Feb;298(2):101507
pubmed: 34929169
Vet Q. 2021 Dec;41(1):181-201
pubmed: 33892621
Front Immunol. 2013 Dec 18;4:470
pubmed: 24391644
Chem Biol. 2005 Mar;12(3):267-77
pubmed: 15797210
Int J Mol Sci. 2021 Jan 20;22(3):
pubmed: 33498183
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Circ Res. 2005 Mar 18;96(5):488-500
pubmed: 15774861
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
Front Microbiol. 2021 Aug 31;12:626553
pubmed: 34531831
J Histochem Cytochem. 2021 Feb;69(2):93-104
pubmed: 32757871
Adv Drug Deliv Rev. 2007 Aug 10;59(8):748-58
pubmed: 17659804
Mol Ther. 2004 Dec;10(6):1011-22
pubmed: 15564133
Comput Struct Biotechnol J. 2021;19:2806-2818
pubmed: 33968333
Matrix Biol. 2014 Apr;35:51-5
pubmed: 24145152
Front Plant Sci. 2020 Jul 07;11:1006
pubmed: 32733513
Biochem J. 2000 Nov 1;351 Pt 3:607-12
pubmed: 11042114
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):
pubmed: 21690215
Angew Chem Int Ed Engl. 2002 Feb 1;41(3):391-412
pubmed: 12491369
Cells. 2021 Jul 17;10(7):
pubmed: 34359983
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
J Infect Public Health. 2021 Jul;14(7):910-921
pubmed: 34119845
Front Public Health. 2021 Jan 11;8:567395
pubmed: 33505949
Viruses. 2019 Jul 01;11(7):
pubmed: 31266258
Int J Exp Pathol. 2015 Feb;96(1):1-10
pubmed: 25546317
J Biol Chem. 1999 Sep 3;274(36):25718-25
pubmed: 10464309
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2020 Mar 6;367(6482):
pubmed: 32139519
Antiviral Res. 2020 Sep;181:104873
pubmed: 32653452
Biochemistry. 2007 Jan 16;46(2):492-501
pubmed: 17209559
J Virol. 2001 Oct;75(19):9187-200
pubmed: 11533182
J Allergy Clin Immunol. 2020 Jul;146(1):18-22
pubmed: 32389590